Method of treating allergic rhinitis in children

FIELD: medicine.

SUBSTANCE: daily in morning hours nasal passages are washed with physiological solution, 10% oil solution of vitamin E in dose 3 drops into each passage is dropped into both nasal passages. After 2 hours transcutaneous impact with constant magnetic field and low-intensity laser irradiation with power 30-80 mW, wavelength 0.85-0.89 mcm, pulse repetition rate 50-80 Hz is carried out on region of projection of thymus, maxillary sinuses, submandibular lymph nodes, spinous process of the third cervical vertebra, mastoid process. Time of impact is 60 seconds per each region. Ozonised olive oil is dropped into each nasal passage in dose 3 drops. After that, by means of light-conducting nozzle performed is impact on anterior parts of inferior nasal conchas with pulse red irradiation with wavelength 0.63-0.65 mcm, pulse power of irradiation at outlet not less than 5 W, pulse repetition rate 50-80 Hz, frequency of light diode modulation - 4-8 Hz. Impact time is 60-120 seconds. Total treatment course is 7 days with 4 month interval, 3 times per year. During the first interval between courses bacterial immunomodulator IRS-19 is introduced in age dose in therapeutic regimen. During the second interval antihomotoxic therapy with drugs Luffel and Lymphomyosot is administered.

EFFECT: method makes it possible to increase treatment efficiency, reduce frequency of disease recurrences, reduce medication load in case of allergic rhinites, which usually require long treatment.

2 tbl, 2 ex

 

The invention relates to medicine, namely to Pediatrics, Allergy, otolaryngology, and is intended for treatment of clinical manifestations of allergic rhinitis in children.

Allergic rhinitis is a common disease. Frequency of symptoms of allergic rhinitis in the Russian Federation is 18-38% (Allergology and immunology. Clinical recommendations for pediatricians. - M.: the Union of pediatricians of Russia, 2008). According to the who currently about 5% of the adult population and 15% of children (more sick boys), allergic diseases (Prof. Lowloss, Institute of immunology MZ the Russian Federation, Moscow, according to the materials of breast cancer, Vol. 11, No. 12, 2003).

The treatment of this disease up to the present time is a serious problem and almost no sufficiently effective treatment methods.

Existing methods of treatment: medication, physical therapy, surgical, etc. often do not give the expected result, so we constantly are searching for and developing new methods, and their combinations.

Currently, progress has been made in drug therapy in such patients.

There is a method of treatment of allergic rhinitis in children (Epicea, "Treatment of allergic rhinitis in children," publishing group "GEOTAR-Media", Moscow, 2007, p.17-53), taken as a prototype, on the make use of an elimination therapy antihistamines I and II generation, stabilizers membranes of the fat cells, vasoconstrictor medications (decongestants), anticholinergics, corticosteroids, taken as a prototype.

The disadvantage of this method is the necessity of using large quantities of drugs, i.e. polipragmazie, an increasing number of side effects, and therapeutic effect is pronounced enough.

The claimed invention is directed to the solution of this problem involves the development of a treatment for allergic rhinitis in children.

The solution to this problem would greatly improve the effectiveness of treatment, to reduce the frequency of relapses, reduce medication burden.

To achieve this, the technical result of the claimed invention is a method of treating allergic rhinitis in children includes the following significant features: including intranasal and oral drug therapy, characterized in that daily in the morning wash out the nasal passages with saline, the fluid in both nasal progress 10% oil solution of vitamin E at a dose of 3 drops every 2 hours spend percutaneous exposure to a constant magnetic field and low-intensity laser radiation power 30-80 mW, a wavelength of 0.85-0.89 microns, cha is the Thoth pulse 50-80 Hz on the projection area of the thymus gland, maxillary sinuses, submandibular lymph nodes, the spinous process of the 3rd cervical vertebra, the mastoid process, the exposure time is 60 seconds each, buried ozonated olive oil in each nostril at a dose of 3 drops, then using a light guide nozzle impinges on the front divisions of the lower turbinates pulse red radiation of a wavelength 0.63-0.65 micron, pulsed radiation power output of not less than 5 W, the pulse repetition rate of 50-80 Hz, frequency of modulation LEDs - 4-8 Hz, the exposure time is 60 to 120 seconds, in the evening after nasal lavage with saline is instilled into both nasal progress 10% oil solution of vitamin E at a dose of 3 drops, a common treatment for 7 days every 4 months, just 3 times a year, in the first interval used bacterial immunomodulator IRS-19 age dose in therapeutic mode, and the second prescribed antihomotoxic therapy, using a combination of drugs Duffel and under given circumstances in the recommended dose.

Between the features and the result is the following causal relationship:

Integrated use 10% oil solution of vitamin E, ozonated olive oil, magnetic therapy, bacterial immunomodulator IRS-19 and antihomotoxic therapy gives offer UEMOA method of treatment of allergic rhinitis effect exceeding the total effect, which increase the effectiveness of treatment and reduce the frequency of relapses.

The inventive method is efficient, cost effective and easily reproducible.

According to the authors the information set of essential features that characterize the essence of the claimed invention, is not known from the prior art, which allows to make a conclusion about conformity of the invention, the criterion of "novelty".

According to the authors of the essence of the invention is not necessary for the expert in the obvious way from the prior art. A collection of characteristics that differ from the prototype of the invention, allows to make a conclusion about its compliance with the criterion of "inventive step".

The set of essential features that characterize the invention, in principle, can be repeatedly used in medicine to achieve a technical result, namely to increase the effectiveness of treatment, improve treatment, reduce the frequency of relapses, which allows to make a conclusion about conformity of the invention, the criterion of "industrial applicability".

As a result of the search in the known solutions have not been found together distinctive features that enhance the effectiveness of treatment Allergy is a mini-rhinitis in children and reducing the frequency of relapses due to the use of a constant magnetic field and low-intensity laser radiation in combination with the local use of ozonated olive oil and vitamin E, as well as bacterial immunomodulator IRS-19

antihomotoxic therapy, which is safe and effective means for the treatment of allergic diseases, in particular for the treatment of allergic rhinitis in children.

A special place is given to medicines with photosensitizing action. Vitamin E plays the role of natural immunoregulatory: stimulates the blast-transformation of T-lymphocytes, production of antibodies by suppressing the suppressor increases the phagocytic activity nautopilot. The highest antioxidant activity exhibits A-tocopherol. Thus, one molecule of A-tocopherol protects 10 thousand molecules of fatty acids, inhibits 60% of the radicals in the membrane (Aneurin and others, 1988, A.Bendicb, 1993).

At low concentrations, ozone activates the antioxidant defense system (AOD) and thus has anti-inflammatory action (Ahellova, 1995; Concentrica, 1995). The effect of ozone leads to activation of mononuclear peripheral blood cells, strengthening specific and nonspecific immune response (V. Bocci et al, 1994; Larinietal, 2001).

To strengthen and consolidate the effect was used

magnetospherically laser apparatus "MILTA-f-8-01"that meets the highest standards of modern medicine: noninvasive, simple control, accuracy and accountability doses of the programme effects on the body. Emitted by the apparatus of low-intensity laser radiation in conditions of a constant magnetic field has a wide range of therapeutic effects: the effect on the intercellular level, activates the sympathetic-adrenal and immune system, increases the concentration of adaptive hormones, that means that complex adaptive and compensatory reactions in the whole organism, aimed at restoring homeostasis, normalization of microcirculation, the elimination of the inflammatory process. All this combined with almost no side effects of treatment, adverse effects inherent in the pharmacological effect of drugs.

Additional terminal "CT" apparatus "MILTA - f - 8-01". Red radiation is traditionally considered to be biologically and clinically very effective physical factor. The major acceptors of red light in human cells are oxygen and catalase. Effects on the body red light allows you to harmonize the circulation of blood and lymph, skin functions, neuroendocrine system and internal organs.

As the drugs entered inhalation, bacterial immunomodulator IRS-19 in an age doses in therapeutic mode of inhalation activates phagocytosis and increases the factors of nonspecific resistance: the incentive of the range the function of T - and b-lymphocytes, production of serum and secretory antibodies, interleukin-1, interferon-alpha.

The drug under given circumstances has a draining action, activating the lymphatic system.

Complex homeopathic preparation Duffel effect on the Constitution of the patient, as also shown in the acute phase of allergic rhinitis. (Arrighi A.Prophylaxe und Therapie der saisonalen alllergischen Rhinitis bei Kindern. Bioi Med 2005; 2:68-70.)

The proposed method of treatment is mainly used in allergic rhinitis in children.

The method is as follows.

We examined 50 patients children from 3 to 18 years. Boys were 31 girls - 18.

All patients randomly were divided into 3 groups, identical in age, sex and severity of the disease. The children in group I (control, n=15) received traditional for this pathology treatment (Mometasone furoate 1 insufflation in each half of nose 1-2 times a day depending on age and an antihistamine 2nd generation cetirizine 5-10 mg 1 time a day for 2 weeks), the children in group II (control, n=15) received antihomotoxic therapy (under given circumstances, 10 drops 3 times a day and Loeffel 1 tablet 3 times a day for 2 weeks)in patients of group III (primary, n=20) treatment was carried out according to the proposed method.

Patients with allergic rhinitis daily UTRAN what their hours wash out the nasal passages with a saline solution, then buried in both nasal progress 10% oil solution of vitamin E at a dose of 3 drops in each. After 2 hours they spend percutaneous exposure to a constant magnetic field and low-intensity laser radiation power 30-80 mW, a wavelength of 0.85-0.89 microns, a pulse repetition rate of 50-80 Hz on the projection area of the thymus gland, maxillary sinuses, submandibular lymph nodes, the spinous process of the 3rd cervical vertebra, the mastoid process, the exposure time is 60 seconds each. After buried ozonated olive oil in each nostril at a dose of 3 drops, then using a light guide nozzle impinges on the front divisions of the lower turbinates pulse red radiation of a wavelength 0.63-0.65 micron, pulsed radiation power output of not less than 5 W, the pulse repetition rate of 50-80 Hz, frequency of modulation LEDs - 4-8 Hz, the exposure time 60-120 seconds. In the evening after nasal lavage with saline is instilled into both nasal progress 10% oil solution of vitamin E at a dose of 3 drops. General treatment for 7 days every 4 months, just 3 times a year, in the first interval used bacterial immunomodulator IRS-19 age dose in therapeutic mode, and the second antihomotoxic therapy - drugs Duffel and under given circumstances in the recommended dose.

The effectiveness conducted by the military treatment was evaluated by the following criteria:

1. On the dynamics of the main clinical symptoms of persistent allergic rhinitis;

2. Analysis follow-up data;

3. By immune modulating effect of therapy;

4. To assess the activity of peroxidation processes and components of antioxidant defense system.

Clinical observation of the children of these groups showed that in children of the main group main clinical symptoms of allergic rhinitis were relieved as compared with the control group significantly earlier (p<0,05): effects of rinorea in 80% of patients were stopped on day 2, stuffy nose 60% of patients on day 5 of magnitolazeroterapii, to the completion of the 1 year - 10% of children only symptom of the disease remained stuffy nose.

In the analysis of follow-up data found that in children of the main group after 3 courses we offer therapy the frequency of exacerbations of allergic rhinitis decreased by 80%. During exacerbations was easier.

Table 1
Comparative analysis of indicators of immune status
Pok LeeThe group of patients
Group I (n=15) Group II (n=15)Group III (n=20)
Before the treatmentAfter the treatmentBefore the treatmentAfter the treatmentBefore the treatmentAfter the treatment
CD3+%61,5±2,761,9±1,362,6±2,864,4±2,564,8±1,869,5±1,2*
CD4+%15,9±0,617,8±0,7*16,3±0,818,1±0,718,3±0,519,2±0,7
CD8+%13,5±0,514,5±0,314,2±0,515,7±0,6*15,4±0,0617,8±0,8*
IgA mg/l0,65±0,040,66±0,070,84±0,030,92±0,02*0,95±0,061,12±0,01*
IgM mg/l 0,51±0,40,62±0,50,63±0,80,86±0,50,61±0,50,86±0,4
IgG mg/l10,85±0,2to 11.56±0,3*12,4±0,613,3±0,812,8±0,514,5±0,6*
*P<0.05 when compared with the results before the treatment

As can be seen from table group III statistically significant increase after treatment, the percentage of T - and b-lymphocytes, the concentration of serum IgA, which indicates moderate immunokorrigiruyuschy, desensibiliziruyuschey the influence of laser radiation in allergic rhinitis in children.

All patients with allergic rhinitis experience stress. At the level of cells is a single complex responses of cell stress, based on damage and closely associated activation of oxidative processes oxidative stress, which plays the role of a starting factor of the inductor subsequent reactive changes and mobilization of antioxidant mechanisms. Thus, using laboratory criteria status of antioxidant activity, intense is vnesti LPO (lipid peroxidation), it is possible within certain limits to objectively assess the severity of the process, to monitor the effectiveness of antioxidant prevention and therapy.

Table 2
Comparative analysis of MDA, hydroperoxides and catalase activity
The group of patientsThe gidroperekisi, umol/lHMM, umol/lCatalase, mkat/l
Group # 1Before the treatment6,205±1,1430,483±2,6610,967±0,55
After the treatment6,258±1,1929,657±1,4212,618±0,38*
Group # 2Before the treatment6,202±1,41528,413±1,4410,717±0,79
After the treatment5,727±0,8825,607±1,5912,367±0,45
Group # 3Before treatment the Oia 6,609±1,05432,967±2,539,984±0,55
After the treatment6,695±1,05226,922±1,624*12,264±0,90*
Background5,237±1,54125,580±1,8312,655±0,56
*P<0.05 when compared with the results before the treatment

From the above data it is seen that in the main group there was a reliable decrease in the total malondialdehyde, normalization of rate of catalase activity. The content of hydroperoxides, in comparison with the control, did not undergo significant changes in all groups were stable.

Example 1

Patient Anastasia P., 3.5 years, turned to the clinic with complaints of nasal congestion, runny nose, paroxysmal sneezing in the morning. History of allergies burdened - dad persistent allergic rhinitis, moderate current. Sick since the age of two, when he first came nasal congestion. The symptoms persist during the year.

Objectively: the patient is in satisfactory condition. Breathing through the nose difficult. The nature of the secret - slimy, watery. Nose view of the and transverse fold. Auscultation - breath puerile, no wheezing. In the analysis of a blood: Erythrocytes lower than the 5.37·1012/l; Hb - 134 g/l; Leukocytes to 10.5·109; e - 9%; p/I - 1%;/I - 39%; l - 47%; m - 4%; ESR - 4 mm/h

The immunological: CD3 - 61% (Rel - 1,5·109/l); CD4 - 33% (Rel - 0,8·109/l); CD8 - 25% (Rel - 0,8·109/l; IgA - 0.64 g/l; IgM - 1.12 g/l; IgG - 6.3 g/l; IgE - 250 IU/ml In a smear from a nose on Cytology revealed a large number of polymorphonuclear leukocytes, eosinophils, coccoid background.

The determination of the activity of antioxidant defenses and GENDER: catalase - 23, 282 IU/rHb; MDA - 26, 667 μmol/l; gidroperekisi - 7,579 (µmol/l).

Diagnosis: Allergic rhinitis, moderate flow, in the acute stage.

The child daily in the morning washed the nasal passages with a saline solution, buried in both nasal progress 10% oil solution of vitamin E at a dose of 3 drops every 2 hours spent percutaneous exposure to a constant magnetic field and low-intensity laser radiation 30 mW, a wavelength of 0.85-0.89 microns, a pulse repetition rate of 50-80 Hz on the projection area of the thymus gland, maxillary sinuses, submandibular lymph nodes, the spinous process of the 3rd cervical vertebra, the mastoid process, the exposure time is 60 seconds each, then buried ozonated olive oil in each nostril in a dose of 3 drops, after using the light guide nozzle which was stastoli on the front divisions of the lower turbinates pulse red radiation of a wavelength 0.63-0.65 micron, pulsed radiation power output of not less than 5 W, the pulse repetition rate of 50-80 Hz, frequency of modulation LEDs - 4 Hz, the exposure time is 60 seconds, in the evening after nasal lavage with saline instilled into both nasal progress 10% oil solution of vitamin E at a dose of 3 drops, a common treatment for 7 days every 4 months, just 3 times a year, in the first interval was used bacterial immunomodulator 1RS-19 age dose in therapeutic mode, and the second antihomotoxic therapy, using a combination of drugs Loeffel 1 tablets X 3 times per day under the tongue and under given circumstances, 10 drops X 3 times a day 30 minutes before meals.

On the background magnetic therapy on day 2 of the phenomenon of rinorea were stopped on day 5 was stuffy nose.

During examination:

The analysis of a blood: Erythrocytes - 4,89·1012/l; Hb - 125 g/l; Leucocytes - 7,5·109; e - 6%; p/I - 2%; with/I - 38%; l - 44%; m - 4%; ESR - 4 mm/h

The immunological: CD3 - 66% (Rel - 1,8·109/l); CD4 - 43% (Rel - 2,2·109/l); CD8 - 335% (Rel - 1,4·109/l; IgA - 1.2 g/l; IgM - 1.3 g/l; IgG - 7,1 g/l; IgE - 125 IU/ml

The determination of the activity of antioxidant defenses and GENDER: catalase - 13,456 IU/rHb; MDA - 20,354 µmol/l; gidroperekisi - 6,514 (µmol/l). The follow-up period: during the year were not observed exacerbations of allergic rhinitis.

Example # 2

Sick Roland, 10 Le is, went to the clinic with complaints of constant stuffy nose, paroxysmal sneezing in the morning, runny nose. History of allergies aggravated by the mother - grandmother bronchial asthma.

Child from 2 pregnancies, 2-urgent delivery, was born with a mass - 3300. After discharge from the hospital was hospitalized in the Department of newborns with a diagnosis of Congenital dermatitis unspecified origins. To 1 month, the skin is cleansed. In 3 years - adenoidectomy, after appeared obstructive bronchitis and stuffy nose. Received symptomatic treatment with slabopolojitelen dynamics. Objectively: the patient is in satisfactory condition. Breathing through the nose difficult. The nature of the secret - slimy, watery. The skin is clean. Rash no. Auscultation - breath puerile, no wheezing. The organs and systems without features.

In the analysis of a blood: Erythrocytes - 3,66·109/l; Hb - 125 g/l; Col. pok-e - 1,02; Leukocytes and 4.4·109; e - 1%; p/I - 4%C/I - 32%; l - 49%; m - 13%; ESR - 5 mm/h

The immunological: CD3 - 59% (Rel - 0,5·10%); CD4 - 29% (Rel - 0,8·109/l); CD8 - 35% (Rel - 0,4·109/l; IgA - 0,91 g/l; IgM - 1.8 g/l; IgG - 10 g/l; IgE - 300 IU/ml

In a smear from a nose on Cytology is dominated by eosinophils, mast cells, basophils.

The determination of the activity of antioxidant defenses and GENDER: catalase - 14,590 IU/rHb; MDA - 34,103 µmol/l; gidroperekisi - of 7.958 (µmol/l). EGNOS: Allergic rhinitis, moderate flow in the acute stage.

The child daily in the morning washed the nasal passages with a saline solution, buried in both nasal progress 10% oil solution of vitamin E at a dose of 3 drops every 2 hours spent percutaneous exposure to a constant magnetic field and low-intensity laser radiation with a capacity of 40 mW, a wavelength of 0.85-0.89 microns, a pulse repetition rate of 50-80 Hz on the projection area of the thymus gland, maxillary sinuses, submandibular lymph nodes, the spinous process of the 3rd cervical vertebra, the mastoid process, the exposure time is 60 seconds each, then buried ozonated olive oil in each nostril in a dose of 3 drops, after using the light guide nozzle impacted the front sections of the lower turbinates pulse red radiation of a wavelength 0.63-0.65 micron, pulsed radiation power output of not less than 5 W, the pulse repetition rate of 50-80 Hz, frequency of modulation LEDs - 8 Hz, the exposure time of 120 seconds, in the evening after nasal lavage with saline instilled into both nasal progress 10% oil solution of vitamin E at a dose of 3 drops, a common treatment for 7 days every 4 months, just 3 times a year, in the first interval used bacterial immunomodulator IRS-19 age dose terapeuticas the ohms mode, and the second antihomotoxic therapy, using a combination of drugs Loeffel 1 tablet X 3 times per day under the tongue and under given circumstances, 10 drops X 3 times a day 30 minutes before meals.

On the background magnetic therapy on day 3 of the phenomenon of rinorea were stopped on day 7 was stuffy nose.

During examination:

The analysis of a blood: Erythrocytes is 4.3·1012/l; Hb - 130 g/l; Leucocytes - 4,5·109; e - 2%; p/I - 2%; with/I - 46%; l - 49%; m -1%; ESR - 4 mm/h

The immunological: CD3 - 72% (Rel - 2,9·109/l); CD4 - 39% (Rel - 2,2·109/l); CD8 - 31% (Rel - 1,2·109/l; IgA - 1.2 g/l; IgM - 1.3 g/l; IgG - 7,1 g/l; IgE - 125 IU/ml Determination of the activity of antioxidant protection of body and GENDER: catalase ~ 12,566 IU/rHb; MDA - 20,354 µmol/l; gidroperekisi - 6,514 (µmol/l). The follow-up period: during the year were not observed exacerbations of allergic rhinitis.

Example # 3

Patient Jura, 17 years old, complained of paroxysmal sneezing throughout the day, constant stuffy nose, shortness of breath.

From history: history of allergies aggravated by the mother and father - parents - intermittent seasonal allergic rhinoconjuctivitis. It hurts to 4 years. Received symptomatic therapy antihistamines with positive dynamics.

About-but the condition is relatively satisfactory. Breathing through the nose difficult. Notes mucous discharge. Dark the circles under the eyes. Auscultation in the lungs breathing hard, no wheezing. The organs and systems without features.

Surveyed:

In the analysis of a blood: Erythrocytes - 4,5·1012/l; Hb - 154 g/l; Leucocytes - 5.2 x 109; e - 3%; p/I - 1%;/I - 47%; l - 45%; m - 4%; ESR - 3 mm/h

The immunological: CD3 - 53% (Rel - 0,6·109/l); CD4 - 27% (Rel - 0,2·109/l); CD8 - 31% (Rel - 0,5·109/l; IgA - 1.2 g/l; IgM - 1.4 g/l; IgG - 14.2 g/l; IgE - 200 IU/ml In a smear from a nose on Cytology: eosinophils, coccoid background.

The determination of the activity of antioxidant defenses and GENDER: catalase - 9,951 IU/rHb; MDA - 26,718 µmol/l; gidroperekisi - 6,117(µmol/l).

Diagnosis: Allergic rhinitis, severe, in the acute stage.

The child daily in the morning washed the nasal passages with a saline solution, buried in both nasal progress 10% oil solution of vitamin E at a dose of 3 drops every 2 hours spent percutaneous exposure to a constant magnetic field and low-intensity laser radiation with a capacity of 80 mW, a wavelength of 0.85-0.89 microns, a pulse repetition rate of 50-80 Hz on the projection area of the thymus gland, maxillary sinuses, submandibular lymph nodes, the spinous process of the 3rd cervical vertebra, the mastoid process, the exposure time is 60 seconds each, then buried ozonated olive oil in each nostril in a dose of 3 drops, after using the light guide nozzle in what was deistvovali on the front divisions of the lower turbinates pulse red radiation of a wavelength 0.63-0.65 micron, pulsed radiation power output of not less than 5 W, the pulse repetition rate of 50-80 Hz, frequency of modulation LEDs - 8 Hz, the exposure time of 120 seconds, in the evening after nasal lavage with saline instilled into both nasal progress 10% oil solution of vitamin E at a dose of 3 drops, a common treatment for 7 days every 4 months, just 3 times a year, in the first interval was used bacterial immunomodulator IRS-19 age dose in therapeutic mode, and the second antihomotoxic therapy, using a combination of drugs Loeffel 1 tablets X 3 times per day under the tongue and under given circumstances, 10 drops X 3 times a day 30 minutes before meals.

On the background magnetic therapy on the 5th day phenomena rinorea were stopped.

During examination:

The analysis of a blood: Erythrocytes - 4,5·1012/l; Hb - 148 g/l; Leucocytes - 4,3·109; e - 3%; p/I - 2%; with/I - 51%; l - 42%; m - 3%; ESR - 8 mm/h

The immunological: CD3 - 76% (Rel - 2,7·109/l); CD4 - 41% (Rel - 1,9·109/l); CD8 - 35% (Rel - 1,2·109/l; IgA - 3.8 g/l; IgM - 2.6 g/l; IgG - 13 g/l; IgE - 80 IU/ml

The determination of the activity of antioxidant defenses and GENDER: catalase - 12,255 IU/rHb; MDA - 19.354 µmol/l; gidroperekisi - 4,653 (µmol/l).

The follow-up period: during the year were not observed exacerbations of allergic rhinitis.

Thus, studies have shown high efficiency is the ability of the proposed method of treatment of allergic rhinitis in children.

The method of treatment of allergic rhinitis in children, including intranasal and oral drug therapy, characterized in that daily in the morning wash out the nasal passages with saline, the fluid in both nasal progress 10%oil solution of vitamin E at a dose of 3 drops in each, 2 h hold percutaneous exposure to a constant magnetic field and low-intensity laser radiation power 30-80 mW, a wavelength of 0.85-0.89 microns, a pulse repetition rate of 50-80 Hz on the projection area of the thymus gland, maxillary sinuses, submandibular lymph nodes, the spinous process of the 3rd cervical vertebra, mastoid the exposure time is 60 s each, buried ozonated olive oil in each nostril at a dose of 3 drops, then using a light guide nozzle impinges on the front divisions of the lower turbinates pulse red radiation of a wavelength 0.63-0.65 micron, pulsed radiation power output of not less than 5 W, the pulse repetition rate of 50-80 Hz, frequency of modulation LEDs 4-8 Hz, the exposure time is 60-120 s, in the evening after nasal lavage with saline is instilled into both nasal progress 10%oil solution of vitamin E at a dose of 3 drops, the total course of treatment 7 days every 4 months, just 3 times a year, in the first interval used is bacterially immunomodulator IRS-19 age dose in therapeutic mode, and the second prescribed antihomotoxic therapy, using a combination of drugs Duffel and under given circumstances within the recommended dosage.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to producing versions of group I Poaceae (holy grass) allergen, also can be used either for specific immunotherapy (hyposensitisation) of patients with grass pollen allergy, or for preventive immunotherapy of grass pollen allergies. The produced versions are characterised by Cys41 Ser, Cys57Ser, Cys69Ser, Cys72Ser, Cys77Ser, Cys83Ser and Cysl39Ser substitutes in a Phi p1 mature protein sequence. Also, a structure of the allergen versions can be presented with no fragments relevant to amino acid residues 1-6, 1-30, 92-104, 115-119, 175-185 and 213-220 or 1-6, 115-119 and 213-220 as a part of a primary sequence of Phi p1 mature protein.

EFFECT: invention allows producing a version of group I Poaceae allergen characterised lower IgE responsiveness as compared with common wild allergen and substantially maintained responsiveness to T-lymphocytes.

8 cl, 9 dwg, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to application of N-acyl derivatives of amino acids of general formula

, where n equals 2 or 3 and their pharmaceutically acceptable salts as anti-allergic, anti-inflammatory and anti-anaphylactic medications.

EFFECT: obtaining pharmaceutical composition for treatment of allergic and inflammatory diseases, for instance such as bronchial asthma, allergic rhinitis, pollinosis, psoriasis.

11 cl, 12 tbl, 19 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (III): , in which D is a benzene ring, 2-pyridone ring, pyridine ring, benzoxalone ring, benzoxadinone ring or benzimidazole ring; R1 denotes carboxy or hydroxy; R2 independently denotes a halogen atom; alkyl optionally substituted with a halogen atom, aryl or alkylamine; alkynyl, optionally substituted alkoxy; hydroxy; carboxy; alkoxy optionally substituted with phenyl, aromatic heterocyclic ring which denotes a 5-6-member aromatic monocyclic carbocyclic ring containing one or two heteroatoms, independently selected from oxygen and nitrogen atoms; alkylsulphonyl; aryloxy; amino optionally substituted with alkyl; acyl optionally substituted with alkyl or alkyloxy; alkyloxycarbonyl; alkanesulphonyl; arylsulphonyl or alkylcarbamoyl; carbamoyl optionally substituted with alkyl, phenyl, cycloalkyl, acetyl, alkanesulphonyl, heteroarylalkyl, cycloalkylalkyl, heteroaryl which denotes a 5-6-member aromatic monocyclic ring containing one or three heteroatoms independently selected from oxygen and nitrogen atoms, and which is optionally substituted with alkyl or cycloalkyl; acylcyano; nitro, aryl; heteroaryl which denotes a 5-6-member aromatic ring containing one or more heteroatoms independently selected from oxygen, sulphur and nitrogen atoms, and which is optionally substituted with alkyl; alkylsulphonyl; morpholinylsulphonyl; non-aromatic heterocyclic group which denotes a 5-6-member non-aromatic heterocyclic ring containing one or more nitrogen atoms and optionally an oxygen and/or sulphur atom; R3 denotes C1-C6alkyloxy, C1-C6alkylthio; R4 denotes a halogen atom or alkyloxy; R5 denotes alkyl; M denotes sulphonyl; L3 independently denotes alkylene optionally containing one oxygen or nitrogen atom, alkenylene, or -N(R7)-; R7 independently denotes a hydrogen atom, alkyl; Y denotes a single bond or CO; Z denotes CH or N; n equals 0 or 1; p equals 0, 1, or 2; q equals 0 or 1; provided that R1 does not denote carboxy when ring D is a benzene ring, -L3- denotes -(O-alkylene)- and the substitution position of L3 and Y is an ortho-position in ring D; to pharmaceutically acceptable salts thereof. The invention also relates to compounds of formula (IV), a pharmaceutical composition, a method of treating diseases associated with the DP receptor, use of compounds in any of the claims 1-17, as well as compounds of general formula (V).

EFFECT: obtaining novel biologically active compounds having DP receptor antagonist activity.

30 cl, 8 ex, 62 tbl

Infant food // 2404785

FIELD: food industry.

SUBSTANCE: invention relates to food and pharmaceutical industry. Infant food composition, containing protein, fats, carbohydrates, nucleotides, nucleosides and nonprotein negatively charged polygalacturonic acid taken at in certain amounts. Application of composition for production of composition for infant feeding. Application of nutrient composition to produce composition for treatment and/or prophylactics of inflammatory disease, diarrhea, eczema and/or atopic dermatitis of a baby.

EFFECT: nutrient composition efficiently imitates protective action of human milk, in particular, against allergies and infections.

9 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds selected from a group comprising 2,3,4,9-tetrahydro-1H-carbazoles of formula I

,

where R1, R2, R3 and R4 independently denote hydrogen, alkyl, alkoxy, halogen, nitro, cyano, trifluoromethyl or formyl, R5 denotes hydrogen, alkyl or -CF3, R6 denotes alkoxy, arylalkoxy, selected from benzyloxy and 1-phenylethoxy, or -NR7R8, R7 and R8 independently denote hydrogen, alkyl, cyanoalkyl, alkenyl, where alkenyl is ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl or 5-hexenyl; aryl, where aryl is a phenyl or naphthyl radical, where said radicals can optionally be monosubstituted with a halogen, alkyl, alkoxy, -CF3, -OCF3, phenylalkyl or phenylcarbonyl; or disubstituted with a substitute independently selected from halogen, alkoxy and phenyl; arylalkyl, where arylalkyl is phenylalkyl, where the alkyl group can optionally be substituted with phenyl; phenylalkyl, where the phenyl ring can optionally be substituted with methylenedioxy; phenylalkyl which is disubstituted with a halogen; phenylalkyl which is monosubstituted with a halogen, -CF3, -OCHF2, alkyl or alkylsulfanyl; or naphthylalkyl; phenylcarbonyl; cycloalkyl, where cycloalkyl is a cyclopentyl or cyclohexyl radical, where said radicals can optionally be substituted with a condensed benzene ring; pyridylalkyl; thienylalkyl; or R7 and R8 together with a nitrogen atom to which they are bonded form a heterocyclic 5-, 6-, 7- or 8-member ring system containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur atoms, wherein said cyclic system can optionally be substituted with (1) one or two condensed benzene rings, where the benzene rings are unsubstituted or substituted with one or two substitutes independently selected from a group comprising C1-C4alkyl, C1-C4alkoxy, halogen, -CF3 and -OCF3; (2) unsubstituted phenyl ring, (3) mono- or disubstituted phenyl ring, where the substitutes are independently selected from a group comprising halogen, C1-C4alkyl, C1-C4alkoxy, -CF3 and -OCF3; or (4) phenylalkyl, where the alkyl group is substituted with phenyl; where the term "alkyl", separately or in any combination, denotes a saturated straight or branched hydrocarbon chain containing 1-7 carbon atoms; where the said alkyl group is unsubstituted unless stated otherwise; or to pharmaceutically acceptable salts thereof. Invention also relates to a pharmaceutical composition and to use of compounds in claim 1.

EFFECT: obtaining novel biologically active compounds having CRTH2 receptor antagonist activity.

13 cl, 5 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology, and can be applied for treatment of allergic rhinitis of domestic etiology. For this purpose in treatment included is allergen-specific immunotherapy with sublingual introduction of cause-significant allergen. Simultaneously hirudotherapy with application of medical leech on skin in region of oral cavity bottom projection is carried out. Procedures are carried out 2 times per week, starting from 0.1 ml 10-6 degree of dissolving of cause-significant allergen and bringing up to 0.5 ml of undissolved allergen, which after that is introduced 1 time per 2 weeks during 3 years.

EFFECT: invention allows to increase treatment efficiency due to increase of cause-significant allergen penetration into system of organs of mucosal immunity of upper airways.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology, and can be used for treating angioedemas. For this purpose introduced are antihistamine preparations, membrane-stabilisers, as well as pulmicort as glucocorticosteroid preparation. Pulmicort is introduced in amount 10 drops per 2 ml of physiological solution by inhalations through nebuliser during 3 minutes. Introduction of pulmicort is carried out daily during 1-3 days.

EFFECT: invention allows fast reduction of gullet and pharynx angioedemas due to direct impact on mucous membranes by said glucocorticosteroid in dose and mode of introduction specially designed for this purpose.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to new compounds of formula I in the form of salt where J means a C1-C2 alkylene; R1 means cyclopentane, cyclohexyl, phenyl or thiophenes; R2 means hydroxy; R3 means a cyclopentane, cyclohexyl, phenyl or thiophenes; with R1 and R3 are not identical, or -CR1R2R3 together form a group of the formula , where Ra means a chemical bond, and Rb means hydroxy; R4 means methyl; R5 means C1 alkyl substituted with -CO-NH-R6; R6 means 5- or 6-membered heterocyclic group that contains in a cycle at least one heteroatom selected from nitrogen, oxygen and sulfur; or J means C1-C2 alkylene; R1 and R3 both mean phenyl; R2 means hydroxy; R4 means methyl, R5 means C1 alkyl substituted with -CO-NH-R9; and R9 means 5- or 6-membered heterocyclic group that contains in a cycle at least one heteroatom selected from nitrogen, oxygen and sulfur. The invention also refers to pharmaceutical composition, to application of compound according to any of clauses 1-3, as well as to method for obtaining a compound of formula I according to clause 1.

EFFECT: obtaining new biologically active compounds having antagonistic activity against muscarinic receptor M3.

7 cl, 21 ex

FIELD: chemistry.

SUBSTANCE: novel 1,2,4-triazole derivatives - protein kinase inhibitors of formula (I) are described, where X - N; Y - CH2, NH, NR or 0; R1 and R2 each independently denote hydrogen; R3 is phenyl, substituted with -CN, 6-member heteroaryl containing 1-2 N atoms, possibly substituted with a 7-member heterocyclyl containing 2 nitrogen atoms, which in turn is substituted with C1-6alkylcarbonyl; R4 is hydrogen; R5 is hydrogen or -CN; and R is a C1-6alkyl group, C1-6alkylcarbonyl group substituted with -CN, or a C3-6cycloalkyl group, a method of inhibiting FLT-3 or c-KIT protein kinase.

EFFECT: obtaining novel compounds and their use in making a medicinal agent for treating or relieving acute myelogenic leucosis.

11 cl, 1 tbl, 13 ex

FIELD: medicine, veterinary science.

SUBSTANCE: agent for treating inflammatory and allergic skin disease in cats and dogs contains Polcortolon as a glucocorticosteroid, Levomycetin and Metronidazole as an antibiotic, excipients - lidocaine hydrochloride, dimethyl formamide, dimethyl sulphoxide, isopropyl alcohol and polyethylene glycol 400, additionally contains calendula extract and Metronidazole, in the following ratio, wt %: Polcortolon 0.01-3.0; Levomycetin 0.1-3.0; lidocaine hydrochloride 0.1-6.0; dimethyl formamide 10.0-15.0; dimethyl sulphoxide 10.0-15.0; calendula extract 0.1-4.0; Metronidazole 0.1-5.0; polyethylene glycol 400 10.0-15.0; isopropyl alcohol - the rest.

EFFECT: invention provides reduced recovery time of allergic and inflammatory functional condition of skin in an animal.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly - to otorhinolaryngology and paediatrics. The method involves the integrated effect of inhalations and magnetotherapy. Dry sodium chloride aerosol is inhaled with using the individual halo inhaler 'Haloneb'. The inhalations are daily. The inhalation procedure lasts for 10-15 minutes in the 2nd halo aerosol generation mode. The therapeutic course is 8-10 inhalations. 5-10 minutes later, the inhalation is followed with low-frequency magnetic field exposure of sinusoidal current shape, frequency 50 Hz, in a continuous mode. Induction is 10-15 mT. The session duration is 10-15 minutes. The procedures are daily. The therapeutic course is 8-10 procedures.

EFFECT: method improves clinical effectiveness ensured by better nasal air passage, reduced oedema and inflammation of the upper-airway mucosa and improved drainage, provided local immunopotentiating and mucolytic action on the nasal and paranasal sinus mucosa.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to otolaryngology, and deals with treatment of chronic recurring inflammatory diseases of nasal mucosa and paranasal sinuses. Method includes preliminarily obtaining of autologic lymphocytes from venous blood of patient, cultivation of obtained lymphocytes together with immunomodulator, preferably immunofan. After that from 0.1 to 3.0 ml of lymphocyte suspension, which contains 106-107 cells/ml, is introduced into paranasal sinuses with intervals between introductions from 2 to 7 days.

EFFECT: method is efficient, including cases of recurring polyps rhynosinutisis, allows to reduce treatment terms, increase remission terms, reduce frequency of appearance of symptoms of main and accompanying disease with reduction of need in other therapy.

4 cl, 3 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology and can be used for treating sinusitis. That is ensured by the integrated treatment that includes ceftriaxone, 1 g of dry substance dissolved in 5 ml of 1% novocaine. Ceftriaxone solution is introduced in a single dosage of 0.5 ml on each side into a skin fold of wing of nose from the vestibule with an insulin needle of external diametre 0.25-0.35 mm.

EFFECT: invention provides higher clinical effectiveness and reduced treatment length due to a certain mode of the lymphotropic introduction of ceftriaxone that allows creating its depot in the immediate proximity from an involved organ with prolonged release into the paranasal sinuses in the therapeutic concentration.

2 ex

FIELD: medicine.

SUBSTANCE: rehabilitation of children with remitted chronic rhinosinusitis is ensured by the administration of Sinupret as a cytoprotector. The preparation is introduced by 25 drops 3 times a day, daily for 24-30 days. Rehabilitation is conditioned by ensured competence of nasal mucosa cells due to newly ascertained reparative ability of Sinupret, with local destructive processes of pavement and columnar epithelium cells and neutrophils be decreased.

EFFECT: higher rehabilitation effectiveness.

5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to stable pharmaceutical composition, which contains as active ingredient phenylephrine in pharmaceutically effective amount and silicified microcrystalline cellulose in amount, effective for reduction of phenylephrine destruction, caused by exposure to oxygen.

EFFECT: phenylephrine tablets by invention demonstrate acceptable physical characteristics, such as form, colour, strength, and satisfactory stability profile.

9 cl, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a nasal pharmaceutical composition for treating or relieving the rhinitis symptoms, containing aqueous suspension of solid particles of fluticasone with the following particle size distribution profile: approximately 10% of particles are smaller than 0.90 microns; approximately 25% of particles are smaller than 1.6 microns; approximately 50% of particles are smaller than 3.2 microns; approximately 75% of particles are smaller than 6.2 microns; approximately 90% of particles are smaller than 10.0 micron; where the composition is available for intranasal introduction in nasal mucosa. Besides the invention relates to the methods of treating said diseases.

EFFECT: composition provides improved therapeutic efficiency at a small dose of fluticasone.

58 cl, 4 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: carboxylic acid compounds are presented by formula (I) where R1 represents (1) hydrogen atom, (2) C1-4alkyl; E represents -CO-; R2 represents (1) halogen atom, (2) C1-6 alkyl, (3) trihalogen methyl; R3 represents (1) halogen atom, (2) C1-6alkyl; R4 represents (1) hydrogen atom; R5 represents (1) C1-6alkyl; represents phenyl; G represents (1) C1-6alkylene; represents 9-12-merous bicyclic heterocycle containing heteroatoms, chosen of 1-4 nitrogen atoms, one or two oxygen atoms; m represents 0 or an integer 1 to 4, n represents 0 or an integer 1 to 4, and i represents 0 or an integer 1 to 11 where R2 can be identical or different provided m is equal to 2 or more, R3 can be identical or different provided n is equal to 2 or more, and R5 can be identical or different provided i is equal to 2 or more; both R12 and R13, independently represent (1) C1-4alkyl, (2) halogen atom, (3) hydroxyl or (4) hydrogen atom, or R12 and R13 together represent (1) oxo or (2) C2-5alkylene and where provided R12 and R13 simultaneously represent hydrogen atom, carboxylic acid compound presented by formula (I), represents a compound chosen from the group including the compounds (1) - (32), listed in cl.1 of the patent claim. Besides the invention concerns a pharmaceutical composition based in the compound of formula I and to application of the compound of formula I for making the pharmaceutical composition.

EFFECT: there are produced new carboxylic acid derivatives with antagonistic activity with respect to DP receptor.

14 cl, 74 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology and physiotherapy. The method involves endonasal introduction of bromide ipratropium by positive-pole endonasal electrophoresis of the solution 1 ml containing bromide ipratropium 0.25 mg/ml. Electrophoresis is performed at current strength not exceeding 2 mA during 10 - 20 minutes. Therapeutic course is 5 daily procedures.

EFFECT: higher clinical effectiveness with decreased number of daily procedures, excludes intillate ingress into gastrointestinal tract.

3 ex, 6 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to new derivatives of imidazo[1,2-c]pyrimidinyl acetic acid of formula (I) or to its salts: , where R1 is ,, in which n is an integer ranging from 0 to 6; Y is aryl, where the said aryl is optionally substituted at a substitutable position with one or more substitutes selected from a group which consists of halogen or C1-6alkyl, optionally substituted with mono-, di- or trihalogen; R2 is hydrogen; R3 is hydrogen or halogen; and R4 is hydrogen. The invention also relates to derivatives of imidazo[1,2-c]pyrimidinyl acetic acid of formula (I-i) or to its salts, to a drug, to use of compounds in paragraph 1, as well as to a drug in form of a standard single dosage.

EFFECT: obtaining new biologically active compounds, which are active towards CRTH2.

23 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to creation of medicinal composition in form of gel for external application, which has anti-inflammatory and antiallergic effect. Gel includes as active substance Xymedon, as antihistamine preparation - diphenhydramine, or clemastine, or cetirizine, gel base with thickener carbopol, polyethylene oxide with molecular weight 400-6000 Da and purified water. Gel also can contain glycerin, ethanol, menthol, preservative - nipagin or benzalkonium chloride, stabiliser and neutralising agent.

EFFECT: gel is characterised by high therapeutic activity in treatment of skin diseases, vasomotor and allergic rhinitis, inflammatory diseases of eyes with allergic manifestations.

5 cl, 2 tbl, 29 ex

FIELD: medicine.

SUBSTANCE: method involves acupuncture treatment of points and regions located on a surface of an auricle corresponding to a thyroid gland, a cervical spine, a hypophysis, a hypothalamus and a brain stem, as well as treatment of a neck and a paravertebral region. In addition, covered are points and regions on the surfaces of the auricle corresponding to two superior cervical, middle cervical and inferior cervical ganglions, lymphatic throat masses, a throat, a tongue, salivary glands, lateral and posterior horns of spinal cord, a reticular formation and a cerebellum. The treatment is combined with low-intensity infrared laser light, and/or with traditional massage, and/or acupuncture, and/or with therapeutic blocks of the reflex regions functionally related to cervical, and/or thoracic, and/or lumbar sympathetic ganglions and parasympathetic cerebral ganglions, and/or of their projections and nerve plexuses related to these vegetative structures, including paravertebral portions in a projection of spinal segments C 1-3, C 5-6, C 7 - Th 1, Th 1 - Th 3, Th 5 - Th 7, Th 11 - L 3, and/or of the regions found along edges of a sternocleidomastoid muscle opposite to a mandibular angle and in their middle, and/or of the region located behind a mastoid of a temporal bone, and/or of a mammary zone, and/or of a submaxillary zone, and/or an area under a malar bone, and/or parasternal and paraclavicular areas. Treatment point is specified by thermography on the basis of hyperthermia or hypothermia, and/or by physical examination on the basis of muscular induration and/or tenderness. Besides, in hypothyroidism, or in excessive functional thyroid tension, or in impaired cold tolerance, or in decrease of body temperature, the treatment involves therapeutic courses including thermal physiotherapeutic procedures.

EFFECT: method provides stable normalisation of thyroid activity with considerable reduction of drug therapy administered.

6 ex, 2 tbl, 3 dwg

Up!